Company intelligence / Profile preview

aTyr Pharma

San Diego, California, United Statesatyrpharma.gcs-web.com ↗

Ownership: Public · ATYR
Employees: ~56
Development stage: Phase 3

Overview

aTyr Pharma’s lead candidate efzofitimod is in global pivotal Phase 3 trials for pulmonary sarcoidosis with topline data expected Q3 2025. The program has shown favorable safety and positive DSMB reviews to date. A separate Phase 2 trial investigates efzofitimod in SSc–ILD. Preclinical and early-stage assets target additional fibrotic and inflammatory diseases as well as oncology through anti-NRP2 antibodies[7][8].

Therapeutic areas: OtherOncologyPulmonologyRheumatology
Modalities: Protein therapeutics (tRNA synthetase-derived biologics)Monoclonal antibodies (anti-NRP2 antibody programs)
Industry: Biotech

Drug pipeline

8 assets

efzofitimod

7 more assets in the full pipeline.

Request access →

Financials

Market cap: $44.7M
Total revenue: $0
Enterprise value: $-1.5M

Beyond the preview

Go deeper on aTyr Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aTyr Pharma.

Explore the full profile